Leading firms, Specialty Ranbaxy tie up

Mumbai: Leading international as well as domestic pharma companies like Eili Lilly, Pfizer Jenssen Cilag, Dr Reddy's and Wockhardt have tied up with Specialty Ranbaxy (SRL) for conducting research and development-related activities of their newly-developed molecules. SRL is a 50:50 joint venture company between Specialty Inc, USA, and the domestic pharma major Ranbaxy.

SRL COO Vidhur Kaushik says all these pharma corporates have tied up for conducting second and third clinical trials of their different molecules in various segments of diseases. The second and third clinical studies of the molecules are very critical because in these stages the dosage, toxity, safety and efficacy profiles are experimented.

Kaushik says these experiments are mainly in the disease segments like anti-diabetic, oncology, leukaemia and anti-TB but was reluctant to divulge the details of the segments in which the corporates are conducting their research.

He says SRL's research-based clinical reference laboratory will develop and provide incisive diagnostic, prognostic and monitoring services to these corporates. SRL is India's first NABL-accredited laboratory, which utilises world-class standard in research activities.

SRL offers more than 1,000 value-added tests ranging from superior technological high-end to general low-end tests to assist corporates in their various research findings. Currently, SRL is specialising in various disease segments like oncology, cytopathology, microbiology, cytogenics and molecular biology clinical pathology and clinical trials.

SRL had carried out clinical trials for other pharma corporates like SmithKline Beecham, and Aventis Pharma. During the last few years many multinational as well as domestic pharma companies have tied up with different Indian research organisations for the development and testing of their different research products.

Last year the Denmark-based pharma major Novo Nordisk had tied up with the Central Drug Research Institute for developing anti-diabetic molecules. Nicholas Piramal had tied up with the Department of Biotechnology. Other research organisations like the Indian Institute of Immunology, the Indian Council of Medical Research and the Indian Institute of Industrial Research have been involved in different research projects for various pharma companies.